Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Synchronous primary lung cancers

M K Ferguson1

  • 1Department of Surgery, University of Chicago.

Chest
|April 1, 1993
PubMed
Summary
This summary is machine-generated.

Synchronous primary lung cancers (SPLCs) are diagnosed in many patients but have poor survival rates. Molecular analysis may help differentiate true SPLCs from metastatic disease for better treatment strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical predictors of donor antibody titre and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial.

Journal of internal medicine·2020
Same author

ISDE Presidential Biography: David B. Skinner, MD.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus·2019
Same author

The 2018 ISDE achalasia guidelines.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus·2018
Same author

Phase II study of neoadjuvant therapy with docetaxel, cisplatin, panitumumab, and radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus (ACOSOG Z4051).

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Extremes of body mass index and postoperative complications after esophagectomy.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus·2017
Same author

Worldwide Esophageal Cancer Collaboration: pathologic staging data.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus·2016
Same journal

A Comparative Study of Radiation Exposure in Conventional and Robotic Bronchoscopy.

Chest·2026
Same journal

Independent Prognostic Contributions of Anti-Ro52 and Anti-MDA5 in Autoimmune-Associated Interstitial Lung Disease.

Chest·2026
Same journal

Lung aeration and gas exchange in SGA or AGA infants with moderate-severe BPD: secondary analysis of the PATH-BPD study.

Chest·2026
Same journal

Lung Cancer Incidence and Mortality after Negative Low-Dose CT Screening Results.

Chest·2026
Same journal

Symptom prevalence and impact on lung cancer risk in the SUMMIT study.

Chest·2026
Same journal

How I Do It: De-escalation of Prostacyclin-Based Therapy in Patients Treated With Sotatercept.

Chest·2026
See all related articles

Area of Science:

  • Thoracic Surgery
  • Oncology
  • Cancer Biology

Background:

  • Synchronous primary lung cancers (SPLCs) affect up to 0.5% of lung cancer patients.
  • Diagnosis often occurs intraoperatively or post-pathologic examination of resected tissue.
  • Despite high rates of early-stage disease, 5-year survival is only 20%.

Purpose of the Study:

  • To investigate the discrepancy between early-stage diagnosis and poor survival in SPLCs.
  • To explore potential reasons for suboptimal outcomes in SPLC patients.
  • To evaluate the utility of molecular techniques in defining SPLC.

Main Methods:

  • Review of SPLC cases and treatment outcomes.
  • Analysis of surgical resection rates and operative mortality.

Related Experiment Videos

  • Exploration of diagnostic accuracy and potential for misdiagnosis (metastasis vs. SPLC).
  • Consideration of molecular profiling, including DNA ploidy analysis.

    • Main Results:

    • Complete surgical resection is feasible in over 90% of SPLC patients.
    • Operative mortality for SPLC resection is low at 2.1%.
    • Two-thirds of SPLC patients present with Stage I or II disease.
    • Overall 5-year survival for SPLC remains significantly low at 20%.

    Conclusions:

    • The poor survival suggests unique SPLC biology or frequent misdiagnosis as metastatic disease.
    • Advanced molecular and biologic analyses are crucial for accurate SPLC patient identification.
    • Optimal therapeutic and preventive strategies for SPLCs require further determination.